Aromatherapy inhaler to reduce distress after a hematopoietic stem cell transplant
Official title: Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Run by Stanford University · NCT05302583 · Data updated 2026-11-12
We will test whether using a lavender or peppermint aromatherapy inhaler in the first days after a hematopoietic stem cell transplant helps reduce cancer-related distress and improve coping.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | CART, Chimeric Antigen Receptor, chemotherapy |
| Locations | 1 site (Stanford, California) |
| Status | Recruiting |
| Started | June 16, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT05302583 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with hematologic malignancies undergoing planned autologous or allogeneic HSCT at Stanford who can consent and are not allergic to lavender or peppermint are the intended participants.
✕Probably not a fit
Patients allergic to lavender or peppermint, those receiving CAR T-cell therapy, those transplanted for germ cell tumors, or patients with atrial fibrillation, scleroderma, or G6PD deficiency are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study provides HSCT patients with a lavender or peppermint aromatherapy inhaler on a single post-transplant day and compares distress and coping to a standard-of-care washout day. The protocol includes an initial aromatherapy day (post-transplant day +1 to +3), a washout day with only standard pharmacologic care, and a follow-up phase day (post-transplant day +3 to +5), with activities occurring on one day per phase. A three-day window for the aromatherapy phases accommodates patients' variable recovery in the immediate post-transplant period. Outcomes focus on short-term changes in distress and coping during the early post-transplant course.
Why it matters
Potential benefit: If effective, aromatherapy inhalers could provide a low-risk, nonpharmacologic option to reduce short-term distress and support coping after HSCT.
How similar studies have gone: Prior small trials of inhaled aromatherapy in cancer and perioperative contexts have shown modest reductions in anxiety and distress, but overall evidence is limited and mixed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Autologous and Allogeneic patients admitted to E1 for planned HSCT * Patients with hematologic malignancies requiring HSCT * No allergies to lavender or peppermint essential oils * Must have received chemotherapy during preparative regimen (single or multi-agent regimen) * Adult patient over 18 years of age * Able to speak, read, and comprehend English * Willing and capable of providing informed consent Exclusion Criteria: * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion * Patients receiving a transplant for a germ cell tumor diagnosis * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration) * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4 * History of scleroderma * History of atrial fibrillation * Known history of G6PD deficiency * Allergic to lavender or peppermint essential oils * Pediatric patient 18 years of age or less * Unable to speak, read, and comprehend English * Unwilling or incapable of providing informed consent
Where it's running
-
Stanford University
Stanford, California, United States Recruiting
Study contacts
- Principal investigator: Anna Oh, PhD, MPH, RN — Stanford University
- Study coordinator: Anna Oh, PhD, MPH, RN
- Email: aoh2@stanford.edu
- Phone: 650-512-6691
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled Aromatherapy During Wound Debridement for Venous Leg Ulcers
This pilot test will see if inhaling essential oils during a sharp wound debridement helps reduce anxiety and pain for adults with venous leg ulcers.
-
Topical lavender oil to help recovery after lung resection
This study tests whether applying lavender essential oil to the skin around the surgical wound for three days after lung surgery can improve recovery and reduce pain.
-
Aromatherapy to support mental health in women undergoing IVF
This will test whether inhaling lavender oil twice daily can reduce anxiety, stress, and depression and improve quality of life for women awaiting IVF.
-
Ruxolitinib-enhanced haploidentical transplant for children and young adults with sickle cell disease
This trial will test whether adding ruxolitinib to a reduced-intensity haploidentical transplant lowers the risk of graft failure in children and young adults with sickle cell disease.
-
Psychosocial and behavioral support for stem cell transplant patients and their family caregivers
This project tests two brief four-session video counseling programs to help stem cell transplant patients and their family caregivers manage care and stick to medical instructions after hospital discharge.
-
Lavender and bergamot aromatherapy to ease anxiety before colonoscopy
This tests whether inhaling lavender or bergamot essential oils before a colonoscopy can reduce anxiety, affect vital signs, and lower feelings of embarrassment in adult patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.